中性粒细胞与淋巴细胞比值及外周血生物标志物与帕博利珠单抗联合伏立诺他治疗头颈癌和唾液腺癌的生存结局相关但与缓解无关
在Ⅱ期试验(NCT02538510)中,25例头颈鳞癌和25例唾液腺癌患者接受帕博利珠单抗联合伏立诺他治疗,其中21例头颈鳞癌和20例唾液腺癌有基线外周血数据。治疗前中性粒细胞与淋巴细胞比值(NLR)和中性粒细胞较高、淋巴细胞和辅助性T细胞较低与更差的总生存(OS)和无进展生存(PFS)相关;NLR较高还预测≥3级不良事件增加,但与客观缓解率(ORR)无关。
要点
- 治疗前NLR和中性粒细胞较高与更差OS和PFS相关。
- 治疗前淋巴细胞和辅助性T细胞较低与更差OS和PFS相关。
- NLR较高预测≥3级不良事件增加,但与ORR无关。
核心结论
- 在帕博利珠单抗联合伏立诺他治疗的头颈鳞癌和唾液腺癌前瞻性队列中,观察到外周血生物标志物与肿瘤结局和毒性之间的新关联。
研究设计与样本
- Ⅱ期试验(NCT02538510)纳入25例复发/转移性头颈鳞癌和25例唾液腺癌患者,接受帕博利珠单抗联合伏立诺他治疗。
- 基线外周血数据在21例头颈鳞癌和20例唾液腺癌中可获取,评估其与≥3级不良事件(按CTCAEv4)、客观缓解率、总生存和无进展生存的关联。
主要发现
- 治疗前中性粒细胞与淋巴细胞比值(NLR)和中性粒细胞较高,以及淋巴细胞和辅助性T细胞较低,与更差的总生存和无进展生存相关。
- NLR较高进一步预测≥3级不良事件发生率增加。
- 未观察到与客观缓解率的相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorinostat on a phase II trial (NCT02538510). EXPERIMENTAL DESIGN: Twenty-five HN and 25 SGCs were treated with pembrolizumab and vorinostat. Baseline peripheral blood was available in 21 HN and 20 SGCs and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv4, objective response rate (ORR), overall survival (OS), and progression-free survival (PFS). RESULTS: Higher pretreatment neutrophil-to-lymphocyte ratio (NLR) and neutrophils, as well as lower pretreatment lymphocytes and T helper cells correlated with worse OS and PFS. Higher NLR further predicted increased rates of G ≥ 3AEs. No correlations with ORR were observed. CONCLUSIONS: In a prospectively evaluated cohort of HN and SGCs treated with pembrolizumab and vorinostat, we observed novel associations between peripheral blood biomarkers and oncologic outcomes and toxicities.
引用
- Pan C, Wu QV, Voutsinas J, et al. Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat. Head Neck. 2022. PMID: 36412064. doi:10.1002/hed.27252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。